Download pdf
Therapeutic role of dabrafenib on thyroid cancer
- 1 Queen's University
* Author to whom correspondence should be addressed.
Abstract
Thyroid cancer, which has a high prevalence of BRAF V600E mutations, is the ninth most frequent cancer worldwide, especially in the aggressive anaplastic thyroid cancer (ATC). The mutation causes continual activation of the MAPK pathway, resulting in unrestricted cell multiplication that leads to the development of tumors. The therapeutic potential of a selective BRAF V600E inhibitor, dabrafenib, has been approved in the treatment of thyroid cancer, especially ATC. The efficacy of dabrafenib was investigated by analyzing various in vivo and in vitro studies and clinical trials. The therapeutic role of dabrafenib on thyroid cancer has been approved in studies involving tumor growth, cell viability, apoptosis, and effects on cancer stem cells (CSCs). Notably, the combination of dabrafenib and MEK inhibitors such as trametinib. significantly inhibited tumor growth and induced apoptosis in thyroid cancer cells. Studies have shown that this combination therapy can reduce tumor volume and target CSCs, which are key to tumor recurrence and drug resistance. Clinical trials have reported improvements in patient status. Dabrafenib, especially in combination with other drugs, offers a better treatment strategy for aggressive thyroid cancer. It enhances the therapeutic effect by effectively targeting the MAPK pathway and CSCs. Future studies may focus on optimizing these combination therapies and exploring their effects and safety to further improve patient outcomes in thyroid cancer treatment.
Keywords
BRAF V600E mutation, Dabrafenib, Anaplastic thyroid carcinoma, Combination therapy, Clinical trials.
[1]. Chen DW, Lang BHH, McLeod DSA, Newbold K and Haymart MR 2023 Lancet. 401 1531-1544
[2]. Gouda MA and Subbiah V P 2023 ESMO Open. 8 100788
[3]. Subbiah V, et al. 2022 Ann Oncol. 33 406-415
[4]. Poulikakos PI, Sullivan RJ and Yaeger R. 2022 Clin. Cancer Res. 28 4618-4628.
[5]. Kimura T, Doolittle WKL, Kruhlak M, Zhao L, Hwang E, Zhu X, Tang B, Wolcott KM and Cheng SY. 2024 Thyroid. 34 484-495.
[6]. Liao Y, Gao Y, Chang A, Li Z, Wang H, Cao J, Gu W and Tang R. 2020 J Cell. Mol. Med. 24 12119-12130.
[7]. Kurata K, Onoda N, Noda S, Kashiwagi S, Asano Y, Hirakawa K and Ohira M. 2016 Int J Oncol. 49 2303-2308.
[8]. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH and Wirth LJ. 2015 Clin. Cancer Res. 21 1028-35.
Cite this article
Wen,B. (2024). Therapeutic role of dabrafenib on thyroid cancer. Theoretical and Natural Science,62,12-18.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).